Plus Therapeutics (NASDAQ:PSTV) Upgraded at D. Boral Capital

D. Boral Capital upgraded shares of Plus Therapeutics (NASDAQ:PSTV) from a hold rating to a buy rating in a report issued on Wednesday, Marketbeat.com reports. D. Boral Capital currently has $5.00 target price on the stock.

A number of other analysts have also issued reports on the stock. Wall Street Zen upgraded shares of Plus Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 16th. Ascendiant Capital Markets lifted their price objective on shares of Plus Therapeutics from $20.00 to $20.50 and gave the company a “buy” rating in a research note on Thursday, June 5th. HC Wainwright dropped their price objective on shares of Plus Therapeutics from $5.50 to $3.00 and set a “buy” rating on the stock in a research note on Friday, June 27th. Finally, Maxim Group dropped their price objective on shares of Plus Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a research note on Monday, August 18th. One research analyst has rated the stock with a Strong Buy rating and four have issued a Buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $7.88.

Plus Therapeutics Stock Performance

NASDAQ PSTV opened at $0.49 on Wednesday. The firm has a market capitalization of $48.78 million, a price-to-earnings ratio of -0.22 and a beta of 0.66. Plus Therapeutics has a one year low of $0.16 and a one year high of $2.31. The company’s 50 day moving average price is $0.48 and its 200 day moving average price is $0.61.

Plus Therapeutics (NASDAQ:PSTV) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.08. The firm had revenue of $1.39 million for the quarter, compared to analysts’ expectations of $1.08 million. Sell-side analysts forecast that Plus Therapeutics will post -2.3 EPS for the current fiscal year.

Insider Activity at Plus Therapeutics

In related news, Director Robert P. Lenk purchased 110,000 shares of Plus Therapeutics stock in a transaction dated Friday, August 22nd. The shares were acquired at an average price of $0.49 per share, with a total value of $53,900.00. Following the completion of the transaction, the director owned 139,327 shares of the company’s stock, valued at approximately $68,270.23. This trade represents a 375.08% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.79% of the company’s stock.

Hedge Funds Weigh In On Plus Therapeutics

A hedge fund recently bought a new stake in Plus Therapeutics stock. Virtu Financial LLC purchased a new position in shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 40,030 shares of the company’s stock, valued at approximately $38,000. Virtu Financial LLC owned about 0.24% of Plus Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 3.28% of the company’s stock.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.